MedTrace Logo

Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers

NCT02446340 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-05-18

No results posted yet for this study

Summary

The purpose of this study is to examine safety outcomes in healthy volunteers after systemic administration of multiple ascending doses of dalazatide.

Conditions

  • Healthy

Interventions

DRUG

dalazatide

Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.

DRUG

placebo

Placebo delivered via subcutaneous administration twice per week for a total of 9 doses

Sponsors & Collaborators

  • Kineta Inc.

    lead INDUSTRY

Principal Investigators

  • Shawn Iadonato, PhD · Kineta Inc.

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02446340 on ClinicalTrials.gov